Adalimumab
- Generic Name
- Adalimumab
- Brand Names
- Amjevita, Cyltezo, Humira, Hyrimoz, Yusimry, Hulio, Hefiya, Libmyris, Imraldi, Amsparity, Idacio, Hukyndra, Amgevita, Yuflyma
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 331731-18-1
- Unique Ingredient Identifier
- FYS6T7F842
- Background
Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor. It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. This drug is frequently known as Humira. It is produced by recombinant DNA technology usi...
- Indication
Adalimumab is indicated for the following conditions:
Adalimumab has also been used off-label to treat Pyoderma gangrenosum.
- Associated Conditions
- Ankylosing Spondylitis (AS), Hidradenitis Suppurativa (HS), Moderate to Severe Chronic Plaque Psoriasis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Ulcerative Colitis, Non-infectious Intermediate, Posterior and Panuveitis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Pyoderma Gangrenosum
- Associated Therapies
- -
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
- Conditions
- Interventions
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 40
- Registration Number
- NCT06100744
- Locations
- 🇺🇸
Arkansas Children's Hospital /ID# 258776, Little Rock, Arkansas, United States
🇺🇸Joe Dimaggio Children's Hospital Hollywood /ID# 260634, Hollywood, Florida, United States
🇺🇸Indiana University Health Riley Hospital for Children /ID# 259067, Indianapolis, Indiana, United States
Effects of TNF Blockade on Human BPH/LUTS
- First Posted Date
- 2023-10-02
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- NorthShore University HealthSystem
- Target Recruit Count
- 70
- Registration Number
- NCT06062875
- Locations
- 🇺🇸
NorthShore University HealthSystem, Glenview, Illinois, United States
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Takeda
- Target Recruit Count
- 150
- Registration Number
- NCT06045754
- Locations
- 🇺🇸
Gastroenterology Research of San Antonio, LLC, San Antonio, Texas, United States
🇺🇸Digestive Health Specialsits, Dothan, Alabama, United States
🇺🇸GI Alliance Sun City, Sun City, Arizona, United States
Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis
- Conditions
- Interventions
- First Posted Date
- 2023-09-14
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Tom Appleton
- Target Recruit Count
- 30
- Registration Number
- NCT06037811
- Locations
- 🇨🇦
St. Joseph's Health Care, London, Ontario, Canada
Therapeutic Monitoring of Infliximab and Adalimumab
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- IRCCS Burlo Garofolo
- Target Recruit Count
- 100
- Registration Number
- NCT06033469
- Locations
- 🇮🇹
Ospedale Maggiore, Bologna, Italy
🇮🇹IRCCS Burlo Garofolo, Trieste, Italy
🇮🇹Ospedale Ca' Foncello, Treviso, Italy
Application of N-of-1 Rheumatoid Arthritis
- Conditions
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Tufts Medical Center
- Target Recruit Count
- 18
- Registration Number
- NCT06016517
- Locations
- 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
Study Evaluation of the Efficacy, Safety and Immunogenicity of Adalimumab in Comparison With Humira®
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Mabscale, LLC
- Target Recruit Count
- 494
- Registration Number
- NCT06005532
- Locations
- 🇷🇺
Regional dermatovenerologic dispensary, Barnaul, Russian Federation
🇷🇺City clinical hospital n.a.Botkin, Moscow, Russian Federation
🇷🇺Reafan, Novosibirsk, Russian Federation
Study to Determine the Pharmacokinetic (PK) Bioequivalence of ABP 501 and Adalimumab (Humira®) in Healthy Adult Japanese Participants
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- Amgen
- Target Recruit Count
- 179
- Registration Number
- NCT05995691
A Study of Adalimumab on Inflammatory Mediators Following a Systemic Endotoxin Challenge
- First Posted Date
- 2023-06-01
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT05884242
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
"Comparison of the Efficacy and Safety of Adalimumab to That of Tocilizumab in Severe Uveitis of Behçet's Disease"
- First Posted Date
- 2023-05-25
- Last Posted Date
- 2023-05-25
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 60
- Registration Number
- NCT05874505
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.